(Q37267425)

English

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia

scientific article published on October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

Alzheimer's disease

0 references

0 references

John Q. Trojanowski

8

object named as

John Q Trojanowski

1 reference

Europe PubMed Central

19 August 2017

author name string

Christopher M Clark

1

1 reference

Europe PubMed Central

19 August 2017

Domenico Pratico

2

1 reference

Europe PubMed Central

19 August 2017

Lesley M Shaw

3

1 reference

Europe PubMed Central

19 August 2017

Susan Leight

4

1 reference

Europe PubMed Central

19 August 2017

Sharon X Xie

5

1 reference

Europe PubMed Central

19 August 2017

Amy Gu

6

1 reference

Europe PubMed Central

19 August 2017

Virginia M-Y Lee

7

1 reference

Europe PubMed Central

19 August 2017

publication date

1 October 2006

1 reference

Europe PubMed Central

19 August 2017

Alzheimer's and Dementia

1 reference

Europe PubMed Central

19 August 2017

2

1 reference

Europe PubMed Central

19 August 2017

287-293

1 reference

Europe PubMed Central

19 August 2017

4

1 reference

Europe PubMed Central

19 August 2017

Frontotemporal dementia: clinicopathological correlations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

The role of biomarkers in clinical trials for Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Fatty acid oxidation in the pathogenesis of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

MRI and CSF studies in the early diagnosis of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Biological markers and the treatment of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

6 September 2017

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

14 September 2017

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Oxidative damage is the earliest event in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2712892

3 September 2018

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19595902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19595902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JALZ.2006.05.2347

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37267425&oldid=2131708500"